Thông tin thuốc gốc
Chỉ định và Liều dùng
Erectile dysfunction
Adult: Initially, 100 mg 15-30 min before sexual intercourse. Dose may be decreased to 50 mg or increased to a max of 200 mg, depending on response. Max dosing frequency: Once every 24 hr.
Nhóm bệnh nhân đặc biệt
Patient receiving α-adrenergic blocking agent: Initially, 50 mg 15-30 min before sexual intercourse. Dose may be adjusted up to 200 mg, depending on response.
Patient receiving moderate CYP3A4 inhibitor (e.g. diltiazem, verapamil): Max: 50 mg once every 24 hr or 100 mg once every 48 hr. All doses are taken 15-30 min before sexual intercourse.
Suy thận
 CrCl (mL/min)   Dosage
 <30  Contraindicated.
Suy gan
Mild to moderate (Child-Pugh class A and B): Initiate w/ the lowest effective dose and adjust according to response. Severe (Child-Pugh class C): Contraindicated.
Cách dùng
tab: May be taken with or without food. Avoid grapefruit juice.
Chống chỉ định
Unstable angina, angina w/ sexual intercourse, CHF, resting hypotension (BP <90 mmHg) or HTN (BP >170/100 mmHg); recent (w/in the last 6 mth) MI, stroke, or life-threatening arrhythmia; other conditions wherein sexual activity is inadvisable, vision loss due to non-arteritic anterior ischaemic optic neuropathy (NAION), hereditary degenerative retinal disorders. Severe renal and hepatic (Child-Pugh class C) impairment. Concomitant use w/ any form of organic nitrate, guanylate cyclase stimulators, potent CYP3A4 inhibitors.
Thận trọng
Patient w/ risk factors or pre-existing CV disease, left-ventricular outflow obstruction, active peptic ulcer, bleeding disorders, risk factors for priapism (e.g. patient w/ sickle cell anaemia, multiple myeloma, leukaemia), penile deformation. Mild to moderate hepatic impairment (Child-Pugh class A and B). Patients receiving α-adrenergic blockers or moderate CYP3A4 inhibitors.
Tác dụng không mong muốn
Significant: CV risk, priapism, sudden vision and hearing loss, NAION, prolonged erection, hypersensitivity reactions.
Nervous: Headache, dizziness.
CV: Flushing, ECG abnormality, transient sitting hypotension.
GI: Viral gastroenteritis.
Resp: Nasal congestion, nasopharyngitis, upper resp tract infection.
Musculoskeletal: Back pain.
Ophthalmologic: Impaired colour discrimination.
Otic: Tinnitus.
Thông tin tư vấn bệnh nhân
This drug may cause dizziness and altered vision, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Assess CV status prior to therapy.
Quá liều
Symptoms: Severe headache, flushing, nasopharyngitis, nasal congestion, back pain, dizziness. Management: Supportive treatment.
Tương tác
Increased exposure w/ moderate CYP3A4 inhibitors (e.g. diltiazem, verapamil). Additive BP-lowering effect w/ α-adrenergic blocking agents (e.g. doxazosin, tamsulosin).
Potentially Fatal: May potentiate the hypotensive effect of any form of organic nitrate, guanylate cyclase stimulators (e.g. riociguat). Significantly increased systemic exposure w/ potent CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, ritonavir).
Tương tác với thức ăn
Grapefruit juice may increases avanafil exposure. Enhanced hypotensive effect w/ alcohol.
Tác dụng
Description: Avanafil inhibits phosphodiesterase type 5-mediated metabolism of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum, resulting in increased cGMP levels which is responsible for smooth muscle relaxation and increased inflow of blood into the corpus cavernosum of the penis during sexual stimulation thereby producing an erection. It has no effect in the absence of sexual stimulation.
Absorption: Rapidly absorbed from the GI tract. Time to peak plasma concentration: W/in 30-45 min.
Distribution: Plasma protein binding: Approx 99%.
Metabolism: Metabolised in the liver by CYP3A4 and to a minor extent by CYP2C isoenzymes into M4 (active) and M16 (inactive) metabolites.
Excretion: Mainly via faeces (approx 62%, as metabolites); urine (approx 21%, as metabolites). Terminal elimination half-life: Approx 5-17 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Avanafil, CID=9869929, https://pubchem.ncbi.nlm.nih.gov/compound/Avanafil (accessed on Jan. 21, 2020)

Bảo quản
Store between 20-25°C. Protect from light.
Phân loại MIMS
Thuốc trị rối loạn cương và rối loạn xuất tinh
Phân loại ATC
G04BE10 - avanafil ; Belongs to the class of drugs used in erectile dysfunction.
Tài liệu tham khảo
Anon. Avanafil. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/08/2017.

Buckingham R (ed). Avanafil. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/08/2017.

Joint Formulary Committee. Avanafil. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/08/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Avanafil. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 01/08/2017.

Stendra Tablet (Mist Pharmaceuticals, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/08/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Avanafil từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in